ONO-7847 Phase 3 Study
Phase 3
- Conditions
- Patient with Malignant Tumor
- Registration Number
- JPRN-jRCT2080220800
- Lead Sponsor
- ONO PHARMACEUTICAL CO.,LTD.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- 344
Inclusion Criteria
1.Patients with malignant tumor who are to be intravenously administered cisplatin as a single dose of 70mg/m2 or higher within 3 hours
2.Patients whose performance status is 0 to 2
Exclusion Criteria
1.In case of patients previously treated with cisplatin, those having no past history of vomiting as of administration of cisplatin
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method